MedTech Industry Pulse: June 2026

Q2 2026 funding held flat at $2.5B against Q1. The 2026 run rate now sits at $10B, down from $12.3B in full year 2025 and $12.5B in 2024. JP Morgan defines MedTech as medical devices, diagnostics, therapeutic digital health, and commercial research tools, excluding healthcare IT and payer or provider software.

Private rounds totaled $2.0B across 97 deals, down $0.4B from Q1 2026 and down $0.65B from Q2 2025. Deal count fell 30 percent year over year, while average deal size rose to roughly $20.6M from $14M, meaning more capital is concentrating in fewer companies.

Total financings fell to $3.8B, down 55.6 percent from Q1 2026 and 54.2 percent from Q2 2025. BioWorld’s tracker spans IPOs, follow-ons, private placements, venture rounds, and loans for companies developing medical devices, diagnostics, and related technologies.

Trusted-approval pathways are expanding. Australia’s TGA, along with Singapore, Malaysia, and Thailand, increasingly streamlines review based on an existing FDA clearance or EU CE mark, and the UK’s emerging reliance pathway leans on prior US, Canada, or Australia approvals. A single FDA or CE decision can now anchor reliance filings across more than ten markets, and companies that sequence their filings well are reaching reimbursement and revenue in those markets months ahead of competitors that file market by market.

Global AI oversight formally diverged in June. Europe deferred its Annex III AI product deadline to August 2028 while keeping devices and IVDs fully in scope of the EU AI Act. The US continued its deregulatory tilt while adding new submission requirements. The UK signaled a flexible, post-market-weighted model over rigid pre-market rules. Japan tightened SaMD validation guidance. China introduced a mandatory, risk-based vigilance system. Separately, human factors validation became a standard part of every FDA review with the June 1 update to eSTAR v7.0, taking effect August 1.

FDA updated eSTAR to v7.0 on June 1, embedding human factors guidance that becomes mandatory August 1. The agency also drafted new Q&A guidance on what health economic information device and combination product manufacturers can share with payors ahead of coverage decisions. The commissioner seat remains open, with the acting commissioner in place.

Parliament adopted a Digital Omnibus on June 16, the first amendment to the AI Act since 2024, pushing the Annex III product deadline for high-risk AI to August 2028. Medical devices and IVDs remain fully in scope. The Commission drafted classification guidelines in June for where device software will land under the high-risk framework, and the European Council gave final approval on June 29, with Official Journal publication expected before August 2026.

The MHRA’s draft pre-market reform consultation closed June 19 and is now in the analysis phase, with adoption targeted for later in 2026. The draft formalizes an international reliance pathway plus predetermined change control plans for AI and software, and signals a flexible, post-market-weighted approach to health AI oversight.

Health Canada advanced establishment licensing reform in June, tightening import and distribution oversight for foreign manufacturers and their Canadian representatives. The agency authorized 481 new devices in Q2, including 22 Class IV devices, and continues shifting toward post-market evidence obligations.

NMPA’s reclassification procedures took effect June 1. A risk-based GMP inspection guideline was drafted June 9, and a draft catalog proposed exempting 11 Class III devices and 66 Class III IVDs from clinical trials. A mandatory, risk-based vigilance framework with periodic safety update reports also took effect.

Japan’s PMDA refreshed core SaMD guidance on June 5 with new AI and machine learning validation requirements and stood up a cross-office AI team. Malaysia widened its device scope to include aesthetic devices, and reliance programs in Malaysia and Thailand moved toward full implementation, while Taiwan’s TFDA opened draft reliance guidelines for comment.